OneSource Specialty Pharma operates as a contract development and manufacturing organization providing drug-device combinations, biologics, sterile injectables, and soft gelatin capsules for global pharmaceutical companies. The core economic engine is the drug-device combination segment, specifically generic semaglutide cartridge filling and device assembly, where the company serves as the primary CDMO partner for the first three approvals in India and Canada. The competitive structure is highly concentrated, as OneSource is among a very small group of global CDMOs offering integrated drug substance and drug product manufacturing for biologics on a single site, alongside being one of the few companies globally with an FDA-approved penicillin plant. Business quality is exceptional and expanding, with management guiding toward a 40% EBITDA margin by FY28, a level sustained by mission-critical components and scarcity in fill-finish capacity.
The economics of this business persist through cycles due to formidable, underappreciated barriers centered on regulatory qualification and manufacturing complexity. Adding a new sterile manufacturing line requires a two-year lead time to design, install, and qualify under stringent regulatory frameworks, meaning competitors cannot replicate this capacity quickly. Switching costs are immense because pharmaceutical customers invest years in tech transfers and regulatory filings tied directly to the specific manufacturing site. This dynamic transforms a commodity peptide input into a specialized, fully assembled drug-device output protected by customer take-or-pay contracts and capacity reservation fees. The market for these GLP-1 products will be an access game rather than a price game for the next few years, as the overall semaglutide supply chain remains severely constrained across cartridges, devices, and fill-finish capacity globally.
The inflection point driving the business over the next 18 to 24 months is the phased commissioning of new manufacturing capacity and the subsequent shift in product mix. By the second quarter of FY27, the second drug-device combination production line will undergo qualification, doubling sterile manufacturing days from 225 to 450. A third line is slated for installation by the end of FY27, bringing total capacity to 675 sterile manufacturing days, while batch sizes scale from 200 liters to 500 liters to increase output per line by 2.5 times. By FY28, the business is targeted to reach $400 million in organic revenue with a 40% EBITDA margin, driven by full utilization of these three lines, base injectable and soft gelatin businesses trending toward $100 million, and meaningful early contributions from a biologics customer funnel that expanded 4x year-on-year.
Management's walk-talk shows a trajectory of near-term delivery misses but long-term target adherence. In January 2026, management explicitly signaled a weak near-term trajectory, reporting a 26% year-on-year revenue decline to INR 290 crores in Q3 FY26 and a PAT loss of INR 472 million because key customers delayed Canadian regulatory approvals. However, by the July 2026 call, Q1 FY27 EBITDA had recovered to INR 1,233 million, up 39% year-on-year, validating the sequential improvement promise. Management has consistently reaffirmed the FY28 target of $400 million in revenue and $160 million in EBITDA without raising it, funding the first phase of the $100 million capex through incremental domestic and international borrowings while reducing the effective interest rate below 9% following four credit rating upgrades.
Earnings visibility is anchored by INR 250 crores in customer advances and a fully committed first DDC line, providing high confidence in the Q4 FY27 exit run rate approaching FY28 guidance numbers. For this trajectory to hold, the second and third DDC lines must qualify on schedule in FY27, and customer regulatory approvals across emerging markets must materialize to absorb the 675 sterile days of capacity. The single most important falsifier is the execution risk surrounding the planned four-month shutdown at the Bangalore injectable site during Q2 and Q3 FY27 to add lyophilization and pre-filled syringe capabilities. If this shutdown delays the broader capacity ramp or if customer approvals slip further into FY28, the operating leverage thesis breaks, leaving the company with upfronted opex and underutilized new lines.
companyname: OneSource Specialty Pharma Limited ticker: ONESOURCE sector: Pharmaceutical Contract Development and Manufacturing (CDMO) OneSource Specialty Pharma Limited is a pure-play, multimodal contract development and manufacturing organization (CDMO) created through a Scheme of Arrangement that became effective on November 27, 2024. The scheme combined the soft gelatin business of Strides Pharma Science Limited, the complex injectables business of Steriscience, and the Biologics-DDC busine...
Read the full report →capex, margin expansion, regulatory approval, market share gain
FY28 revenue guided at $400 million with 40% EBITDA margin driven by capacity expansion and emerging market demand
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Onesource Specialty Pharma Ltd. and 4,900+ companies.
5-day free pass. No card required.